The author is in the Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, USA. gudkov@ccf.org
Drug discovery is either an exact business that is based on detailed knowledge of target structure or it is a fishing expedition that uncovers new drugs through screening of random compounds for their biological effect on target function. Isolation of a new p53 activator with anticancer properties strengthens the reputation of this second approach (pages 1321−1328).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
